Wednesday, August 4, 2010

Green Baron Buy Opportunities:  Recent “Stock Alert” Freedom Environmental (BB: FRDM) pulled back yesterday to close at .028 per share for no apparent reason following its huge rally over the past few weeks.  After news announcements of acquisitions that should make this a .28 stock, FRDM pulled back from recent levels of nearly .05 per share to close below .03.  We continue to view FRDM as a buy on dips, and yesterday we just got one. 

“Stock Alert” Aspire International (PK: APIT) announced news yesterday that it will bring financials and filings up to date and be in full reporting compliance with all regulatory authorities.  At .35 or under we still believe this is a steal.  To read full news announcement go to: http://finance.yahoo.com/news...

 

“Trading Alert” Update

 

A5 Laboratories, Inc.

(BB: AFLB)

News Alert: A5 Laboratories Inc. Update

Before the open of trading yesterday, The Green Baron Report released its new “Trading Alert” A5 Laboratories, Inc. (BB: AFLB).  Although AFLB held steady, it was a far cry from the huge move up we saw in our last “Trading Alert” right out of the gate.  Volume was strong at nearly 200,000 shares, its second largest volume day in its short trading history. 

Before the open yesterday, A5 Labs issued a press release to update its business development activities for the month of July.  We urge members to see this release reprinted below, and consider entry at the current price level.

Aug 3, 2010 7:00:00 AM

MONTREAL, QUEBEC -- (MARKET WIRE) -- 08/03/10 -- A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) is pleased to provide an update on the company's business development activities for the month of July.

On July 5, 2010 the company closed the acquisition of the Contract Research Organization (CRO) and laboratory assets as well as intellectual property relating to a method for the production of interferon products. Subsequently, the company entered into agreements with two CRO customers to provide a comprehensive range of services.

Most recently A5 Labs submitted a provisional patent application to protect its technology for the production of interferon-based products. A5 Labs' lead product, VI-1718, has potential broad based applications for the treatment of certain types of cancer as well as multiple sclerosis and viral infections. During the month of July the company secured over $250,000 in equity financing.

Dr. Richard Azani, President and CEO of A5 said "I am very excited about the progress of our company in its first month of operations as a public entity. The filing of our patent was a crucial step, but equally important, the pharmaceutical companies are validating our ability to provide top notch services by entering into contracts with us and the investment community is validating our viability as a public company by providing us early financing. We look forward to expanding our management team and continuing to develop our production technology towards commercialization of interferon-based products in the coming months."

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contacts:

A5 Laboratories Inc.

Investor Relations

1-877-331-8777

ir@a5labs.com